Abstract:Background: Although oxidative phosphorylation (OXPHOS) is the main ATP source in primary prostate cancer, as the tumor progresses to castration resistance and/or metastatic disease, glycolysis becomes increasingly prevalent. Dependence on glycolysis can further increase under hypoxic conditions found in advanced cancers. We previously demonstrated that a novel small molecule, BKIDC-1553, inhibits proliferation and tumor growth of prostate cancer cell lines and xenografts through a hexokinase-2 (HK2) dependent inhibition of glycolysis. HK2 is a glucose 6-phosphorylating enzyme that works in conjunction with glucose transporter-1 (GLUT1) to drive glycolysis in cells. While our previous work suggests that BKIDC-1553 works primarily through a HK2 dependent mechanism, the objective of this current project is to further examine how expression and function of HK2 and GLUT1 are altered in response to BKIDC-1553 treatment. Methods: Hypoxic conditions are common in late-stage prostate cancer. Effects of hypoxia on cell proliferation and expression levels of HK1, HK2, and GLUT1 were examined with and without BKIDC-1553 treatment. To examine role of HK1, HK2, and GLUT1 in response to BKIDC-1553 treatment, we created CRISPR knockouts and shRNA knockdowns of HK1 and HK2 in the LNCaP prostate cancer cell line. GLUT1 was inhibited using a commercially available inhibitor, BAY-876. PCR and Western blots were used to confirm expression levels of HK1, HK2, and GLUT1. MTS proliferation assays were used to examine effect of KO and KD on response to BKIDC-1553 and BAY-876. Results: GLUT1 levels, but not HK1 or 2, increased at 72 hrs under hypoxic conditions. HK1, HK2, and GLUT1 levels all increased in cells in response to 144 hrs of BKIDC-1553 compared with 72 hrs treatment in both normoxic and hypoxic conditions. The KO and KD studies were all conducted in normoxic conditions. Westerns blots demonstrated that HK2 KO, but not HK1 KO, results in increased levels of GLUT1. HK1 or HK2 KD, however, did not alter GLUT1 levels. HK2 KD cells, with GLUT1 levels remaining the same, displayed less growth inhibition than control cells in response to BKIDC-1553 treatment, while HK2 KO cells, with increased levels of GLUT1, remained sensitive to BKIDC-1553. Because GLUT1 levels increase in response to HK2 KO, we wanted to see if inhibiting GLUT1 in these cells could decrease their proliferation. We found that KO cells were indeed more sensitive to growth inhibition of BAY-876. Conclusion/Summary: These studies indicate that KO of HK2 increases levels of GLUT1. These cells remain sensitive to BKIDC-1553 treatment, which could in part be due to the cells' continued reliance on glycolysis through increased GLUT1. A continued reliance on glycolysis allows BKIDC-1553 to continue to inhibit cell growth. Future studies examining how combination treatment with BKIDC-1553 and BAY-876 affects growth of advanced prostate cancer cells is underway. Citation Format: Cynthia Sprenger, Mika Munari, Shihua Sun, Kathryn Soriano Epilepsia, Stephen Plymate. Alterations in glycolytic pathway enzymes and metabolic plasticity in prostate cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 448.

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer

ADP-dependent Glucokinase Controls Metabolic Fitness in Prostate Cancer Progression

Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity

Beyond DNA Repair: DNA-PK Function in Cancer

DNA-PK as an Emerging Therapeutic Target in Cancer

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer

Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased α‐Catenin

Exploring a Novel Role of Glycerol Kinase 1 in Prostate Cancer PC-3 Cells

The Catalytic Subunit of DNA-PK Regulates Transcription and Splicing of AR in Advanced Prostate Cancer.

A Novel Role for Pyruvate Kinase M2 As a Corepressor for P53 During the DNA Damage Response in Human Tumor Cells*

DNA methyl-transferases (DNMTs) as potential therapeutic vulnerability in prostate cancer.

A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer

PRKAR2B‐HIF‐1α Loop Promotes Aerobic Glycolysis and Tumour Growth in Prostate Cancer

Targeting Tumor Metabolism for Cancer Treatment: is Pyruvate Dehydrogenase Kinases (pdks) a Viable Anticancer Target?

Abstract 6014: PLK1-dependent phosphorylation of PRMT5 promotes DNA damage response in prostate cancer

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

Abstract 448: Alterations in glycolytic pathway enzymes and metabolic plasticity in prostate cancer progression

The DNA methylation landscape of advanced prostate cancer

DNA-PKcs: A Multi-Faceted Player in DNA Damage Response

Abstract 3373: Protein kinase D1 alleviate etoposide induced DNA damage through up regulation of alpha-catenin